The Puzzling Hypoglycemia: A Detective's Guide to the Low Glucose

A Systematic Approach to Diagnosing Non-Diabetic Hypoglycemia

Dr Neeraj Manikath , claude.ai

Abstract

Hypoglycemia in patients without diabetes presents a diagnostic challenge that requires methodical investigation. This review provides a systematic approach to evaluating unexplained hypoglycemia, emphasizing the critical importance of Whipple's triad, the diagnostic utility of the supervised fast, recognition of factitious causes, and identification of rare but important etiologies including insulinomas and non-islet cell tumors. Understanding the biochemical fingerprints of different causes enables clinicians to navigate this diagnostic puzzle with confidence.

---

The Critical First Step: Verifying a True Low with the "Whipple's Triad" Checklist

The foundation of hypoglycemia investigation rests upon Whipple's triad, first described in 1938 and remaining the gold standard for establishing genuine hypoglycemia.(1) Many patients present with symptoms they attribute to low glucose, but without documented hypoglycemia during symptomatic episodes, the diagnosis remains speculative.

Whipple's Triad consists of:

1. Symptoms consistent with hypoglycemia (neuroglycopenic or autonomic)
2. Documented low plasma glucose concentration (typically <55 mg/dL or 3.0 mmol/L)
3. Relief of symptoms with correction of hypoglycemia

Clinical Pearl: Home glucose meter readings suggesting hypoglycemia should always be confirmed with simultaneous laboratory plasma glucose measurement. Meters can be inaccurate at low ranges, and this verification prevents pursuing extensive workups for pseudohypoglycemia.(2)

The symptoms of hypoglycemia follow a predictable hierarchy. Autonomic symptoms (tremor, palpitations, anxiety, diaphoresis, hunger) typically emerge first as glucose falls below 60 mg/dL. As glucose continues declining below 50 mg/dL, neuroglycopenic symptoms predominate: confusion, difficulty concentrating, behavioral changes, seizures, and ultimately coma.(3) Patients with recurrent hypoglycemia may develop hypoglycemia unawareness, losing the early autonomic warning symptoms.

Diagnostic Hack: Create a "symptom diary" for patients to record symptoms alongside capillary glucose measurements, but insist on laboratory confirmation during a symptomatic episode before proceeding with invasive testing. This saves time, resources, and prevents unnecessary anxiety.

Oyster: Postprandial symptoms occurring 2-5 hours after meals, especially carbohydrate-rich meals, suggest reactive hypoglycemia. However, true documented hypoglycemia during these episodes is uncommon. Most such patients have postprandial syndrome without true hypoglycemia and require reassurance rather than extensive investigation.(4)

---

The 72-Hour Fast: A Practical Guide to Setting It Up and Interpreting the Results

The supervised fast remains the diagnostic gold standard for evaluating suspected endogenous hyperinsulinism.(5) When performed correctly, it provides definitive biochemical evidence to distinguish among various causes of hypoglycemia.

Setting Up the Fast

Patient Preparation:

• Hospitalization or supervised outpatient setting with continuous observation
• Baseline measurements: glucose, insulin, C-peptide, proinsulin, beta-hydroxybutyrate, sulfonylurea screen
• Allow only calorie-free, caffeine-free beverages
• Continue essential medications (but hold hypoglycemic agents)
• Monitor glucose every 6 hours initially, then every 1-2 hours when glucose falls below 60 mg/dL

Clinical Pearl: Most patients with insulinomas develop hypoglycemia within 48 hours; extending beyond 72 hours rarely provides additional diagnostic yield.(6)

Termination Criteria

The fast should be terminated when:

1. Plasma glucose ≤45 mg/dL with symptoms, OR
2. Plasma glucose <55 mg/dL if Whipple's triad previously documented, OR
3. 72 hours elapsed without hypoglycemia

Critical samples at termination include:

• Plasma glucose
• Insulin
• C-peptide
• Proinsulin
• Beta-hydroxybutyrate
• Sulfonylurea/meglitinide screen

Interpreting the Results

Normal Response: Glucose remains >55 mg/dL, or if glucose falls, insulin suppresses appropriately (<3 μU/mL), C-peptide suppresses (<0.6 ng/mL), and ketones rise (beta-hydroxybutyrate >2.7 mmol/L).(7)

Endogenous Hyperinsulinism (Insulinoma):

• Glucose <55 mg/dL
• Insulin ≥3 μU/mL (inappropriately elevated)
• C-peptide ≥0.6 ng/mL (elevated)
• Proinsulin ≥5 pmol/L
• Beta-hydroxybutyrate <2.7 mmol/L (ketone suppression)
• Negative sulfonylurea screen

Diagnostic Hack: Calculate the insulin-to-glucose ratio. A ratio >0.3 (with insulin in μU/mL and glucose in mg/dL) strongly suggests inappropriate insulin secretion, though this should not replace the absolute values.(8)

Exogenous Insulin Administration:

• Glucose <55 mg/dL
• Insulin elevated
• C-peptide <0.6 ng/mL (suppressed!)
• Negative sulfonylurea screen

Sulfonylurea/Meglitinide Use:

• Glucose <55 mg/dL
• Insulin elevated
• C-peptide elevated
• Positive sulfonylurea screen

Oyster: Proinsulin levels are particularly valuable. Insulinomas often have inefficient prohormone processing, resulting in proinsulin levels >5 pmol/L or proinsulin constituting >22% of total insulin immunoreactivity. Normal or low proinsulin in the setting of hyperinsulinemic hypoglycemia suggests exogenous insulin administration.(9)

---

The Accidental Detective: Uncovering Factitious Hypoglycemia and Munchausen's

Factitious hypoglycemia represents a challenging diagnosis requiring clinical astuteness, compassion, and sometimes forensic investigation. Patients may surreptitiously administer insulin or oral hypoglycemic agents, creating genuine biochemical hypoglycemia with devastating consequences if unrecognized.

Clinical Clues

Red Flags for Factitious Hypoglycemia:

• Healthcare workers or patients with access to insulin
• Erratic, unpredictable hypoglycemic episodes
• Hypoglycemia resistant to usual measures
• Psychiatric history or secondary gain
• Discrepancy between reported and witnessed symptoms
• Reluctance to have witnessed blood draws

Pearl: Interview family members separately. Observers may report behaviors or access to medications the patient hasn't disclosed.(10)

Biochemical Fingerprints

Exogenous Insulin Administration: The C-peptide becomes the detective's most valuable tool. Endogenous insulin production always releases equimolar amounts of C-peptide and insulin. Commercial insulin preparations contain no C-peptide.

The Tell-Tale Pattern:

• Very high insulin levels (often >100 μU/mL)
• Suppressed C-peptide (<0.6 ng/mL)
• Low or unmeasurable proinsulin
• Insulin-to-C-peptide ratio >1 (normally <1)

Oyster: Insulin antibodies may develop with repeated exogenous insulin exposure, even in patients without diabetes. Testing for insulin antibodies can provide supporting evidence, though their absence doesn't exclude factitious administration.(11)

Sulfonylurea/Meglitinide Surreptitious Use:

• Elevated insulin and C-peptide (mimics insulinoma)
• Positive sulfonylurea screen (essential test!)
• May require testing for multiple agents (glipizide, glyburide, glimepiride, repaglinide, nateglinide)

Diagnostic Hack: When suspecting factitious hypoglycemia, consider witnessed blood draws with immediate specimen processing and chain-of-custody protocols. Some patients have been known to inject insulin into IV tubing or blood collection tubes.(12)

Approaching the Patient

Confronting a patient with suspected factitious disorder requires extraordinary sensitivity. Direct accusation often results in denial, evasion, or the patient seeking care elsewhere while continuing dangerous behavior.

Strategy:

• Employ a non-judgmental, therapeutic approach
• Frame findings as "puzzling" or "unusual patterns"
• Involve psychiatry early for co-management
• Emphasize concern for patient safety rather than blame
• Document thoroughly for medicolegal protection

Pearl: Sometimes the diagnosis becomes apparent only through exclusion of all other possibilities combined with supportive biochemical evidence. A negative 72-hour fast in a patient with documented hypoglycemia during unsupervised periods should raise suspicion.(13)

---

Insulinoma Workup: Connecting the Dots Between Insulin, C-Peptide, and Proinsulin

Insulinomas are rare neuroendocrine tumors with an incidence of approximately 1-4 per million person-years, but they represent the most common cause of endogenous hyperinsulinemic hypoglycemia in adults.(14) The diagnostic journey from clinical suspicion to surgical cure requires systematic biochemical confirmation followed by tumor localization.

Biochemical Diagnosis

The supervised fast, as detailed earlier, provides definitive biochemical diagnosis. The characteristic pattern includes:

• Inappropriate insulin secretion during hypoglycemia
• Elevated C-peptide (proving endogenous origin)
• Elevated proinsulin (>5 pmol/L or >22% of insulin immunoreactivity)
• Suppressed beta-hydroxybutyrate (<2.7 mmol/L)
• Negative sulfonylurea screen

Clinical Pearl: The proinsulin level holds particular diagnostic value. Insulinomas have disorganized prohormone processing, releasing more proinsulin than normal beta cells. A proinsulin >5 pmol/L in the presence of hypoglycemia has 83% sensitivity and 96% specificity for insulinoma.(15)

Calculating Diagnostic Indices

While not replacing absolute values, several indices assist interpretation:

Amended Insulin-Glucose Ratio: (Insulin in μU/mL × 100) / (Glucose in mg/dL - 30)

• Value >50 suggests insulinoma (older literature; less used currently)

HOMA-IR (Homeostatic Model Assessment): Generally not useful during hypoglycemia but can help assess insulin resistance if fasting glucose normal

Oyster: Some insulinomas are small enough to evade detection initially, and some patients have nesidioblastosis (beta-cell hyperplasia) rather than a discrete tumor. Both produce identical biochemical patterns and require expert surgical intervention.(16)

Tumor Localization

Once biochemical diagnosis is established, localization determines surgical approach.

First-Line Imaging:

1. Multiphasic CT scan (pancreatic protocol with arterial, venous, and delayed phases): Sensitivity 70-80%
2. MRI with gadolinium: Sensitivity 85-95%, particularly valuable for small tumors
3. Endoscopic ultrasound (EUS): Sensitivity 80-95%, especially for tumors <2 cm; allows simultaneous fine-needle aspiration(17)

Second-Line Procedures:

• Selective arterial calcium stimulation with hepatic venous sampling (ASVS): Gold standard for localization when imaging is negative or equivocal; sensitivity >90% but requires specialized expertise(18)
• Intraoperative ultrasound: Performed by experienced surgeon during exploration
• Somatostatin receptor imaging (68Ga-DOTATATE PET/CT): Variable sensitivity (50-70%) for insulinomas as not all express somatostatin receptors abundantly(19)

Diagnostic Hack: For elusive tumors, combining EUS with ASVS provides near-100% detection rates. ASVS also regionalizes the tumor to pancreatic head, body, or tail, guiding surgical approach even when precise localization isn't achieved.(20)

Preoperative Management

Controlling hypoglycemia before surgery is essential:

• Frequent small meals with complex carbohydrates
• Continuous dextrose infusion if severe
• Diazoxide 150-400 mg daily (opens K-ATP channels, suppresses insulin release); monitor for fluid retention
• Octreotide 50-100 μg subcutaneously BID-TID (use cautiously; may paradoxically worsen hypoglycemia in some insulinomas)(21)

Pearl: Most insulinomas (90%) are benign, solitary, and <2 cm. Surgical cure is achieved in >95% of cases. Malignant insulinomas (<10%) are typically larger (>2 cm), have liver metastases, and require oncologic management.(22)

---

Non-Islet Cell Tumors: The Unusual Suspects Causing Hypoglycemia

Non-islet cell tumor hypoglycemia (NICTH) represents a fascinating paraneoplastic syndrome where tumors produce factors causing profound, life-threatening hypoglycemia. Though rare, recognition is crucial as treatment differs fundamentally from insulinoma management.

Pathophysiology

Most NICTH results from tumor production of incompletely processed insulin-like growth factor 2 (IGF-2), termed "big IGF-2."(23) This large molecular form:

• Crosses the capillary endothelium more readily than normal IGF-2
• Binds insulin receptors, causing hypoglycemia
• Suppresses growth hormone and consequently IGF-1 production
• Suppresses insulin and C-peptide secretion

Oyster: The biochemical pattern is pathognomonic: hypoglycemia with suppressed insulin, suppressed C-peptide, suppressed growth hormone, and low IGF-1 with elevated or inappropriately normal IGF-2. The IGF-2-to-IGF-1 ratio typically exceeds 10 (normal <3).(24)

Associated Tumors

Most Common Culprits:

1. Mesenchymal tumors: Solitary fibrous tumors (hemangiopericytomas), fibrosarcomas, leiomyomas, particularly retroperitoneal or intrathoracic masses(25)
2. Hepatocellular carcinoma: Large tumors with extensive hepatic replacement
3. Adrenocortical carcinoma: Advanced disease
4. Gastrointestinal tumors: Gastric, colorectal carcinomas

Clinical Pearl: NICTH typically occurs with large tumors (often >10 cm) and advanced disease. The hypoglycemia is often severe, refractory to oral intake, and requires continuous intravenous dextrose. Weight loss and cachexia are prominent features.(26)

Diagnostic Approach

Critical Laboratory Pattern:

• Glucose <55 mg/dL with symptoms
• Insulin <3 μU/mL (appropriately suppressed)
• C-peptide <0.6 ng/mL (suppressed)
• Beta-hydroxybutyrate low (<2.7 mmol/L) – because IGF-2 suppresses lipolysis and ketogenesis
• Growth hormone suppressed
• IGF-1 low or low-normal
• IGF-2 normal or elevated (misleading!)
• IGF-2-to-IGF-1 ratio >10

Diagnostic Hack: The suppressed ketones during hypoglycemia with suppressed insulin is the key paradox. Normally, insulin suppression during fasting allows lipolysis and ketogenesis. IGF-2, however, has insulin-like effects that prevent appropriate ketone production, creating "non-ketotic hypoglycemia."(27)

Imaging

Tumors causing NICTH are usually evident on imaging:

• CT chest/abdomen/pelvis with contrast
• MRI for soft tissue characterization
• PET-CT if occult malignancy suspected

Management

Acute Management:

• High-rate continuous dextrose infusion (often requiring central access)
• Frequent feedings with complex carbohydrates
• Glucocorticoids (prednisolone 30-60 mg daily) – stimulate gluconeogenesis and reduce IGF-2 bioavailability(28)
• Growth hormone (0.1-0.3 mg/kg/day) – increases IGF-1 and IGF-binding proteins, reducing free IGF-2(29)

Pearl: Glucagon is ineffective in NICTH because hepatic glycogenolysis is already maximally stimulated by the IGF-2 effect. Diazoxide likewise doesn't help since insulin secretion is already suppressed.(30)

Definitive Management: Tumor debulking or resection when possible provides the only cure. Even partial tumor reduction can dramatically improve hypoglycemia. For unresectable tumors, systemic therapy targeting the underlying malignancy may reduce IGF-2 production and ameliorate hypoglycemia.(31)

Oyster: Some patients with hepatocellular carcinoma develop hypoglycemia through increased glucose consumption by the large tumor mass rather than IGF-2 production. Hepatic failure with impaired gluconeogenesis also contributes. The distinction matters less clinically as management focuses on the underlying malignancy.(32)

---

Conclusion

Approaching hypoglycemia in non-diabetic patients requires methodical detective work. Confirming Whipple's triad prevents wild-goose chases. The supervised fast provides definitive biochemical phenotyping, distinguishing endogenous hyperinsulinism from exogenous causes and non-insulin-mediated hypoglycemia. The pattern of insulin, C-peptide, and proinsulin acts as a biochemical fingerprint, pointing toward insulinoma, factitious administration, or sulfonylurea ingestion. Recognition of non-islet cell tumor hypoglycemia, though rare, can be life-saving. By systematically following this diagnostic algorithm, clinicians can solve even the most puzzling hypoglycemia cases, providing patients with accurate diagnoses and appropriate management.

---

References

1. Whipple AO. The surgical therapy of hyperinsulinism. J Int Chir. 1938;3:237-276.

2. Cryer PE, Axelrod L, Grossman AB, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2009;94(3):709-728.

3. Kalra S, Mukherjee JJ, Venkataraman S, et al. Hypoglycemia: The neglected complication. Indian J Endocrinol Metab. 2013;17(5):819-834.

4. Brun JF, Fedou C, Mercier J. Postprandial reactive hypoglycemia. Diabetes Metab. 2000;26(5):337-351.

5. Service FJ. Hypoglycemic disorders. N Engl J Med. 1995;332(17):1144-1152.

6. Hirshberg B, Livi A, Bartlett DL, et al. Forty-eight-hour fast: the diagnostic test for insulinoma. J Clin Endocrinol Metab. 2000;85(9):3222-3226.

7. Service GJ, Thompson GB, Service FJ, et al. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med. 2005;353(3):249-254.

8. Vezzosi D, Bennet A, Fauvel J, Caron P. Insulin, C-peptide and proinsulin for the biochemical diagnosis of hypoglycaemia related to endogenous hyperinsulinism. Eur J Endocrinol. 2007;157(1):75-83.

9. Guettier JM, Gorden P. Insulin secretion and insulin-producing tumors. Expert Rev Endocrinol Metab. 2010;5(2):217-227.

10. Yanagisawa N, Fujita K, Watanabe M, et al. Factitious hypoglycemia in a patient with diabetes mellitus and schizophrenia. Intern Med. 2015;54(19):2507-2510.

11. Redmon JB, Nuttall FQ. Autoimmune hypoglycemia. Endocrinol Metab Clin North Am. 1999;28(3):603-618.

12. Marks V, Teale JD. Hypoglycemia: factitious and felonious. Endocrinol Metab Clin North Am. 1999;28(3):579-601.

13. Frier BM. Morbidity of hypoglycemia in type 1 diabetes. Diabetes Res Clin Pract. 2004;65 Suppl 1:S47-52.

14. Service FJ, McMahon MM, O'Brien PC, Ballard DJ. Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc. 1991;66(7):711-719.

15. Kao PC, Taylor RL, Service FJ. Proinsulin by immunochemiluminometric assay for the diagnosis of insulinoma. J Clin Endocrinol Metab. 1994;78(5):1048-1051.

16. Won JGS, Tseng HS, Yang AH, et al. Clinical features and morphological characterization of 10 patients with noninsulinoma pancreatogenous hypoglycaemia syndrome (NIPHS). Clin Endocrinol (Oxf). 2006;65(5):566-578.

17. Rostambeigi N, Thompson GB. What should be done for an insulinoma? Surg Clin North Am. 2019;99(2):223-237.

18. Guettier JM, Kam A, Chang R, et al. Localization of insulinomas to regions of the pancreas by intraarterial calcium stimulation: the NIH experience. J Clin Endocrinol Metab. 2009;94(4):1074-1080.

19. Christ E, Wild D, Forrer F, et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab. 2009;94(11):4398-4405.

20. Doppman JL, Miller DL, Chang R, et al. Insulinomas: localization with selective intraarterial injection of calcium. Radiology. 1991;178(1):237-241.

21. Gorden P, Skarulis MC, Roach P, et al. Plasma proinsulin-like component in insulinoma: a 25-year experience. J Clin Endocrinol Metab. 1995;80(10):2884-2887.

22. Falconi M, Eriksson B, Kaltsas G, et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2016;103(2):153-171.

23. Daughaday WH, Emanuele MA, Brooks MH, et al. Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia. N Engl J Med. 1988;319(22):1434-1440.

24. Marks V, Teale JD. Tumours producing hypoglycaemia. Diabetes Metab Rev. 1991;7(2):79-91.

25. Dynkevich Y, Rother KI, Whitford I, et al. Tumors, IGF-2, and hypoglycemia: insights from the clinic, the laboratory, and the historical archive. Endocr Rev. 2013;34(6):798-826.

26. de Groot JW, Rikhof B, van Doorn J, et al. Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases. Endocr Relat Cancer. 2007;14(4):979-993.

27. Fukuda I, Hizuka N, Ishikawa Y, et al. Clinical features of insulin-like growth factor-II producing non-islet-cell tumor hypoglycemia. Growth Horm IGF Res. 2006;16(4):211-216.

28. Teale JD, Marks V. Glucocorticoid therapy suppresses abnormal secretion of big IGF-II by non-islet cell tumours inducing hypoglycaemia (NICTH). Clin Endocrinol (Oxf). 1998;49(4):491-498.

29. Shames JM, Dhurandhar NR, Blackard WG. Insulin-secreting bronchial carcinoid tumor with widespread metastases. Am J Med. 1968;44(4):632-637.

30. Hoff AO, Vassilopoulou-Sellin R. The role of glucagon administration in the diagnosis and treatment of patients with tumor hypoglycemia. Cancer. 1998;82(7):1585-1592.

31. Bodnar TW, Acevedo MJ, Pietropaolo M. Management of non-islet-cell tumor hypoglycemia: a clinical review. J Clin Endocrinol Metab. 2014;99(3):713-722.

32. Nauck MA, Reinecke M, Perren A, et al. Hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-I in a patient with metastasizing large-cell carcinoma of the lung. J Clin Endocrinol Metab. 2007;92(5):1600-1605.